Search Results - "Shabaneh, Tamer"

Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma by Molodtsov, Aleksey K., Khatwani, Nikhil, Vella, Jennifer L., Lewis, Kathryn A., Zhao, Yanding, Han, Jichang, Sullivan, Delaney E., Searles, Tyler G., Preiss, Nicholas K., Shabaneh, Tamer B., Zhang, Peisheng, Hawkes, Aaron R., Malik, Brian T., Kolling, Fred W., Usherwood, Edward J., Wong, Sandra L., Phillips, Joseph D., Shirai, Keisuke, Angeles, Christina V., Yan, Shaofeng, Curiel, Tyler J., Huang, Yina H., Cheng, Chao, Turk, Mary Jo

“…The nature of the anti-tumor immune response changes as primary tumors progress and metastasize. We investigated the role of resident memory (Trm) and…”
Get full text

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors by Steinberg, Shannon M, Shabaneh, Tamer B, Zhang, Peisheng, Martyanov, Viktor, Li, Zhenghui, Malik, Brian T, Wood, Tamara A, Boni, Andrea, Molodtsov, Aleksey, Angeles, Christina V, Curiel, Tyler J, Whitfield, Michael L, Turk, Mary Jo

“…Acquired resistance to BRAF inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be…”
Get full text

Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib by Shabaneh, Tamer B, Downey, Sondra L, Goddard, Ayrton L, Screen, Michael, Lucas, Marcella M, Eastman, Alan, Kisselev, Alexei F

“…The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause…”
Get full text

Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies by Goddard, Erica T, Linde, Miles H, Srivastava, Shivani, Klug, Grant, Shabaneh, Tamer B, Iannone, Santino, Grzelak, Candice A, Marsh, Sydney, Riggio, Alessandra I, Shor, Ryann E, Linde, Ian L, Guerrero, Marissa, Veatch, Joshua R, Snyder, Annelise G, Welm, Alana L, Riddell, Stanley R, Ghajar, Cyrus M

“…The period between "successful" treatment of localized breast cancer and the onset of distant metastasis can last many years, representing an unexploited…”
Get more information

Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation by Yeh, Albert C, Koyama, Motoko, Waltner, Olivia G, Minnie, Simone A, Boiko, Julie R, Shabaneh, Tamer B, Takahashi, Shuichiro, Zhang, Ping, Ensbey, Kathleen S, Schmidt, Christine R, Legg, Samuel R W, Sekiguchi, Tomoko, Nelson, Ethan, Bhise, Shruti S, Stevens, Andrew R, Goodpaster, Tracy, Chakka, Saranya, Furlan, Scott N, Markey, Kate A, Bleakley, Marie E, Elson, Charles O, Bradley, Philip H, Hill, Geoffrey R

“…Allogeneic T cell expansion is the primary determinant of graft-versus-host disease (GVHD), and current dogma dictates that this is driven by…”
Get more information

Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks by Jaeger-Ruckstuhl, Carla A, Lo, Yun, Fulton, Elena, Waltner, Olivia G, Shabaneh, Tamer B, Simon, Sylvain, Muthuraman, Pranav V, Correnti, Colin E, Newsom, Oliver J, Engstrom, Ian A, Kanaan, Sami B, Bhise, Shruti S, Peralta, Jobelle M C, Ruff, Raymond, Price, Jason P, Stull, Sylvia M, Stevens, Andrew R, Bugos, Grace, Kluesner, Mitchell G, Voillet, Valentin, Muhunthan, Vishaka, Morrish, Fionnuala, Olson, James M, Gottardo, Raphaël, Sarthy, Jay F, Henikoff, Steven, Sullivan, Lucas B, Furlan, Scott N, Riddell, Stanley R

“…The interaction of the tumor necrosis factor receptor (TNFR) family member CD27 on naive CD8 T (Tn) cells with homotrimeric CD70 on antigen-presenting cells…”
Get more information

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells by Kraus, Marianne, Bader, Juergen, Geurink, Paul P, Weyburne, Emily S, Mirabella, Anne C, Silzle, Tobias, Shabaneh, Tamer B, van der Linden, Wouter A, de Bruin, Gerjan, Haile, Sarah R, van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F, Overkleeft, Herman, Driessen, Christoph

“…Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome…”
Get full text

An epoxide hydrolase secreted by Pseudomonas aeruginosa decreases mucociliary transport and hinders bacterial clearance from the lung by Hvorecny, Kelli L, Dolben, Emily, Moreau-Marquis, Sophie, Hampton, Thomas H, Shabaneh, Tamer B, Flitter, Becca A, Bahl, Christopher D, Bomberger, Jennifer M, Levy, Bruce D, Stanton, Bruce A, Hogan, Deborah A, Madden, Dean R

“…The opportunistic pathogen Pseudomonas aeruginosa colonizes the lungs of susceptible individuals by deploying virulence factors targeting host defenses. The…”
Get more information

Acidosis potentiates the host proinflammatory interleukin-1β response to Pseudomonas aeruginosa infection by Torres, Iviana M, Patankar, Yash R, Shabaneh, Tamer B, Dolben, Emily, Hogan, Deborah A, Leib, David A, Berwin, Brent L

“…Infection by Pseudomonas aeruginosa, and bacteria in general, frequently promotes acidification of the local microenvironment, and this is reinforced by…”
Get full text

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis by Shabaneh, Tamer B., Molodtsov, Aleksey K., Steinberg, Shannon M., Zhang, Peisheng, Torres, Gretel M., Mohamed, Gadisti A., Boni, Andrea, Curiel, Tyler J., Angeles, Christina V., Turk, Mary Jo

“…Abstract Regulatory T cells (Treg) are critical mediators of immunosuppression in established tumors, although little is known about their role in restraining…”
Get full text

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma by Steinberg, Shannon M, Zhang, Peisheng, Malik, Brian T, Boni, Andrea, Shabaneh, Tamer B, Byrne, Katelyn T, Mullins, David W, Brinckerhoff, Constance E, Ernstoff, Marc S, Bosenberg, Marcus W, Turk, Mary Jo

“…A growing body of evidence suggests that BRAF inhibitors, in addition to their acute tumor growth-inhibitory effects, can also promote immune responses to…”
Get more information

Safety switch optimization enhances antibody-mediated elimination of CAR T cells by Shabaneh, Tamer B, Moffett, Howell F, Stull, Sylvia M, Derezes, Thomas, Tait, Leah J, Park, Spencer, Riddell, Stan R, Lajoie, Marc J

“…Activation of a conditional safety switch has the potential to reverse serious toxicities arising from the administration of engineered cellular therapies,…”
Get full text

Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones by van der Linden, Wouter A, Willems, Lianne I, Shabaneh, Tamer B, Li, Nan, Ruben, Mark, Florea, Bogdan I, van der Marel, Gijs A, Kaiser, Markus, Kisselev, Alexei F, Overkleeft, Herman S

“…Syringolins, a class of natural products, potently and selectively inhibit the proteasome and show promising antitumour activity. To gain insight in the mode…”
Get more information

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity by Shabaneh, Tamer Basel, Stevens, Andrew R, Stull, Sylvia M, Shimp, Kristen R, Seaton, Brandon W, Gad, Ekram A, Jaeger-Ruckstuhl, Carla A, Simon, Sylvain, Koehne, Amanda L, Price, Jason P, Olson, James M, Hoffstrom, Benjamin G, Jellyman, David, Riddell, Stanley R

“…BackgroundThe paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell therapy of solid tumors necessitates careful preclinical evaluation…”
Get full text

Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib by Mirabella, Anne C., Pletnev, Alexandre A., Downey, Sondra L., Florea, Bogdan I., Shabaneh, Tamer B., Britton, Matthew, Verdoes, Martijn, Filippov, Dmitri V., Overkleeft, Herman S., Kisselev, Alexei F.

“…Proteasomes degrade the majority of proteins in mammalian cells, are involved in the regulation of multiple physiological functions, and are established…”
Get full text

CDDO-Me Redirects Macrophage Activation by Santiesteban, Gretel Maria Torres, Shabaneh, Tamer, Bhandari, Rajan, Liby, Karen, Turk, Mary Jo, Pioli, Patricia

“…Abstract Melanoma tumors are highly immunogenic, making them an attractive target for immunotherapy. However, many patients do not mount robust clinical…”
Get full text

Microbiota-Specific T Cells Contribute to Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation by Yeh, Albert C, Koyama, Motoko, Waltner, Olivia, Minnie, Simone A, Boiko, Julie, Shabaneh, Tamer B, Takahashi, Shuichiro, Zhang, Ping, Ensbey, Kathleen, Schmidt, Christine, Legg, Samuel, Sekiguchi, Tomoko, Nelson, Ethan, Bhise, Shruti, Stevens, Andrew, Goodpaster, Tracy A, Chakka, Saranya R., Furlan, Scott N., Markey, Kate A., Bleakley, Marie, Elson, Charles O, Hill, Geoffrey R

“…Background: Allogeneic T-cell expansion is the primary determinant of graft-versus-host disease (GVHD), and current dogma dictates that this is driven by…”
Get full text

Reprograming of Tumor-Associated Macrophages in Human BrafV600EMutant Melanoma by Santiesteban, Gretel Maria Torres, Bhandari, Rajan, Yang, Heetaek, Spezza, Paul, Shabaneh, Tamer Basel, Liby, Karen, Turk, Mary Jo, Pioli, Patricia A

“…Abstract Melanoma tumors are highly immunogenic, making them an attractive target for immunotherapy. However, many patients do not mount robust clinical…”
Get full text

Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors by Steinberg, Shannon M., Shabaneh, Tamer B., Zhang, Peisheng, Martyanov, Viktor, Li, Zhenghui, Malik, Brian T., Wood, Tamara A., Boni, Andrea, Molodtsov, Aleksey, Angeles, Christina V., Curiel, Tyler J., Whitfield, Michael L., Turk, Mary Jo

“…Acquired resistance to BRAF V600E inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be…”
Get full text

The Role of Regulatory T Cells in BRAFV600E-Driven Melanoma Outgrowth by Shabaneh, Tamer Basel

“…Oncogenic driver mutations sustain chronic mitogenic signaling and typify neoplastic disease. Recent studies began to shed light on the propensity of oncogenic…”
Get full text